Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for OSM drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OSM ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View OSM Products |
| Gene Delivery | OSM Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View OSM Products |
| Benchmark Ab | Anti-OSM (Sequence of GSK2330819) Recombinant positive control. |
View OSM Products |
| Validator | OSM siRNA Set For knockdown verification. |
View OSM Products |
| Related Target A | OSMR (Oncostatin M Receptor) Critical signaling co-receptor mediating type II OSM receptor activation. |
View OSMR Products |
| Related Target B | LIFR (Leukemia Inhibitory Factor Receptor) Alternative co-receptor forming the type I OSM receptor complex. |
View LIFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and verified theoretical MW |
| Subfamily counter screening (IL-6 family) | Homolog panel proteins (LIF, IL-6, IL-11) strictly verified by mass spectrometry and sequence analysis |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives | Validated siRNA included for specificity and target knockdown checks |
Live Oncostatin M (OSM) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OSM therapeutics is intensifying, with major players shifting focus from traditional systemic anti-cytokine therapies to targeted interventions in mucosal inflammation and tissue remodeling. As first-generation therapies reach the clinic, the next wave of R&D is targeting anti-TNF refractory inflammatory bowel disease (IBD) and fibrotic disorders.
Oncostatin M (OSM) serves as a key driver of inflammation and tissue remodeling, signaling through its two receptor complexes: OSMR-gp130 and LIFR-gp130. Blocking the ligand OSM itself offers a direct route to neutralizing both signaling pathways, making it a highly attractive target for patients who fail standard anti-TNF-alpha biological treatments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Neutralizing) | GSK, Janssen | Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis | Receptor binding inhibition assay (Need high-purity recombinant OSM and OSMR/LIFR proteins) |
| Bispecific Antibody (OSM x TNF) | Innovative Biotech Startups | Refractory Crohn's Disease, Ulcerative Colitis | Dual-targeting validation (Need highly stable Human OSM and TNF-alpha antigens) |
| Small Molecule Inhibitors (JAK/STAT pathway downstream) | Pfizer, AbbVie | Myelofibrosis, Inflammatory Diseases | Selectivity assay (Need mutant and wild-type kinase domains and cell-based reporter assays) |